Fundraising Fox
Ratio Therapeutics
Boston, US · Delaware corporation · 6 known investors
Find your way into Ratio Therapeutics
261 people in our graph can introduce you to the Ratio Therapeutics team.
Sign up to see every warm intro you have to Ratio Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Ratio Therapeutics team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Ratio Therapeutics develops radiopharmaceuticals for oncology, working on targeted radiochemistry, discovery, and preclinical and clinical development. The company operates in the biotech and medtech space focused on molecular imaging and radiotherapy.
Founders & leadership
JH
Jack Hoppin, Ph.D.Chairman, Chief Executive Officer
WC
William CupeloChief Business Officer
MF
Matthias FriebeChief Technology OfficerDr. Matthias Friebe is Chief Technology Officer of Ratio Therapeutics, a radiopharmaceutical developer focused on oncology. He previously served as VP of Radiochemistry Research at Bayer HealthCare, co-founded Piramal Imaging where he led chemistry and manufacturing operations, and brings over two decades of experience in radiotherapy and molecular imaging probe development from roles at the Swiss Federal Institute of Technology and Harvard Medical School; he holds a PhD in Radiopharmaceutical Chemistry from the Technical University Dresden.
SH
Scott HolbrookChief Commercial and Manufacturing OfficerScott Holbrook is Chief Commercial and Manufacturing Officer at Ratio Therapeutics, a developer of radiopharmaceuticals for oncology. He has over 25 years of experience in molecular imaging and therapeutics, including target identification, GMP manufacturing, regulatory affairs, clinical development, and post-approval manufacturing.
MB
Marc BeckerChief Financial and Operating Officer
SM
Scott MacDonaldNamed on SEC filing
WC
William CowanNamed on SEC filing
SW
Susan WhoriskeyNamed on SEC filing
AH
Albert HolmanNamed on SEC filing
Investors · 6
Catalio Capital ManagementreportedNew York
How we know: offering press articles · press coverage · Not right? Tell us
Also in the syndicate · 5
Bristol Myers SquibbDuquesne Family OfficeEli LillyEli Lilly and CompanyWasatch Group
Reported raises · per SEC filings
Form D private placements$120.7M disclosed across 2 rounds · 2023–2026
▶$70MraisedJul 2026 · 57 investors · PharmaceuticalsRule 506(b)
▶$70MraisedJul 2026 · 57 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- John W. HoppinExecutive Officer, Director
- John BabichDirector
- Marc BeckerExecutive Officer
- Scott MacDonaldExecutive Officer
- William CowanDirector
- Susan WhoriskeyDirector
- Albert HolmanDirector
- Allan GreenDirector
- Brandon IngersollDirector
- Offering amount
- $70M
- Amount sold
- $70M
- First sale
- Jul 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$50.7MraisedDec 2023 · 46 investors · PharmaceuticalsRule 506(b)
▶$50.7MraisedDec 2023 · 46 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Allan GreenDirector
- Shawn HillierExecutive Officer
- Albert HolmanDirector
- Matthias FriebeExecutive Officer
- John W. HoppinExecutive Officer, Director
- Jacob HestermanExecutive Officer
- John BabichExecutive Officer, Director
- Reed MalleckExecutive Officer
- Scott HolbrookDirector
- John GarveyExecutive Officer
- Susan WhoriskeyDirector
- Offering amount
- $50.7M
- Amount sold
- $50.7M
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
Atara BiotherapeuticsAtara Biotherapeutics develops allogeneic T-cell immunotherapies using its proprietary EBV T-cell platform to harness the immune system for treating disease. The company focuses on next-generation cell-based therapies designed for patients worldwide.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Aro BiotherapeuticsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
RelayRelay Therapeutics develops the Dynamo platform, which applies motion-based drug design principles to discover therapeutic drugs by integrating protein dynamics simulations with experimental and computational techniques. The platform serves pharmaceutical and biotech researchers seeking to accelerate drug discovery across multiple phases of development.
Companies working in the same space as Ratio Therapeutics.
In the news
Frequently asked questions
- What does Ratio Therapeutics do?
- Ratio Therapeutics develops radiopharmaceuticals for oncology, working on targeted radiochemistry, discovery, and preclinical and clinical development. The company operates in the biotech and medtech space focused on molecular imaging and radiotherapy.
- Who founded Ratio Therapeutics?
- Ratio Therapeutics was founded by John Babich, Jack Hoppin, Jack Hoppin, Ph.D..
- Who are Ratio Therapeutics's investors?
- Ratio Therapeutics's investors include Catalio Capital Management.
- How much funding has Ratio Therapeutics raised?
- Ratio Therapeutics has disclosed $120.7M raised across 2 rounds.
- Where is Ratio Therapeutics headquartered?
- Ratio Therapeutics is headquartered in Boston, US.